Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854041 | 0.91 | ALDH1A1 (0.49) | ALDH1A1HRH3KCNH2KDM4EKMT2A | |
| SCHEMBL853399 | 0.90 | ALDH1A1 (0.53) | ALDH1A1HRH3KCNH2ADRA1A | |
| SCHEMBL854577 | 0.87 | POLB (0.51) | POLBMAPTHRH3KCNH2ADRA1A | |
| SCHEMBL853555 | 0.86 | PARP1 (0.46) | POLBMAPTHRH3KCNH2ADRA1A | |
| SCHEMBL854689 | 0.86 | ALDH1A1 (0.44) | ALDH1A1POLBHRH3KCNH2KMT2A | |
| SCHEMBL855356 | 0.86 | ALDH1A1 (0.44) | ALDH1A1POLBHRH3KCNH2ADRA1A | |
| SCHEMBL855099 | 0.84 | HRH3 (0.48) | ALDH1A1HRH3 | |
| SCHEMBL854035 | 0.82 | PARP1 (0.49) | ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL855616 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HRH3KDM4EKMT2A | |
| SCHEMBL854452 | 0.79 | SERPINE1 (0.54) | ALDH1A1HRH3KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432765-B1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-03-02 | — | — | EP | claimed |
| US-8592416-B2 | Isoquinolin-1 (2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-26 | — | — | US | claimed |
| US-20120157454-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | US | claimed |
| EP-2432765-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-03-28 | — | — | EP | claimed |
| WO-2010133647-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-25 | — | — | WO | claimed |
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| EP-2432765-B1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-03-02 | — | — | EP | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8993594-B2 | Isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| WO-2015036759-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-03-19 | — | — | WO | disclosed |
| US-20140045846-A1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-13 | — | — | US | disclosed |
| US-8592416-B2 | Isoquinolin-1 (2H)-one derivatives as PARP-1 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-26 | — | — | US | disclosed |
| US-20120157454-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-21 | — | — | US | disclosed |
| EP-2432765-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133647-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | ALDH1A1 1976/4885POLB 1000/4885MAPT 2345/4885 |
| US-20120157454-A1 | ISOQUINOLIN-1 (2H) -ONE DERIVATIVES AS PARP-1 INHIBITORS | PARP1, PARP2, PARP11 | ALDH1A1 299/4885POLB 113/4885MAPT 1619/4885 |
| US-20140045846-A1 | ISOQUINOLIN-1(2H)-ONE DERIVATIVES AS PARP-1 INHIBITORS | PARP1, PARP2, PARP11 | ALDH1A1 299/4885POLB 113/4885MAPT 1619/4885 |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP1 | ALDH1A1 1784/4885POLB 909/4885MAPT 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.